Hyaluronic Acid and Galacto-Xyloglucan Eyedrop Efficacy in Young-Adult Oral Contraceptive Users of Childbearing Age

Abstract

To assess the efficacy of 0.4% hyaluronic acid and 0.2% galacto-xyloglucan for the subjective symptoms of dry eye disease and tear film invasive and noninvasive signs in 34 young-adult oral contraceptive users of childbearing age, a prospective, longitudinal, single-blind, clinical study was performed in a population of childbearing-age oral-contraceptive consumers. Subjective dry eye disease questionnaires, and invasive and noninvasive tear film assessments were reported before and after six weeks of hyaluronic acid with galacto-xyloglucan (HA-GX) treatment versus hyaluronic acid alone (HA). HA-GX treatment resulted in a greater decrease in the ocular surface disease index (17.01 ± 11.36 score points, p < 0.01) than the HA variation (11.61 ± 11.18 score points, p < 0.01). The standard patient evaluation of eye dryness also decreased more in the HA-GX group (4.06 ± 5.50 score points, p < 0.01) than in the HA alone group (0.70 ± 3.16, p = 0.21). Regarding noninvasive break-up time (NIBUT), the HA-GX group’s first NIBUT achieved an increase of 1.75 ± 1.16 s, p < 0.01, while the HA-alone group increased by only 0.54 ± 1.01 s, p < 0.01. The HA-GX group’s mean NIBUT reported an increase of 3.72 ± 5.69 s, p < 0.01; however, the HA-alone group achieved 2.19 ± 5.26 s, p = 0.05. Hyaluronic acid in combination with galacto-xyloglucan significantly decreased subjective dry eye disease symptoms and increased first and mean NIBUT compared to hyaluronic acid alone. Galacto-xyloglucan added efficacy in young-adult childbearing-age oral contraceptive users.

Tear film layers and meibomian gland assessment in patients with type 1 diabetes mellitus using a noninvasive ocular surface analyzer: a cross-sectional case–control study

“…The noninvasive analysis of the tear film was performed through the Integrated Clinical Platform (ICP) Ocular Surface Analyzer (OSA) from SBM System® (Orbassano, Torino, Italy) [16][17][18]. OSA provides a complete noninvasive assessment of the ocular surface by combining several tests for the diagnosis of DED.…”

Exploring the Cutting Edge of Vision Science: New Developments in Diagnostics and Treatment of Ocular Surface in Dry Eye Disease

“…It also helps keep the eye surface moist and comfortable, which is essential for good vision [6]. There are several factors that can affect tear film stability, including age, hormonal changes [16,28,29], medications [30,31] and certain medical conditions. Dry eye disease is one of the most common causes of tear film instability and is more common in women than in men, especially after menopause [16,28,29].…”

“…To treat dry eye disease, doctors may recommend the use of eye drops or ointments to supplement the natural tear film [6,9]. There are several types of eyedrops available, including artificial tears, which are designed to mimic the natural tear film; lubricating drops, which help to moisturize the eye; and anti-inflammatory drops, which reduce inflammation and redness [28][29][30][31][32][33].…”